# Comparing Efficacy and Safety of CTO0303 in Pediatric Subjects

> **NCT06609525** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Taejoon Pharmaceutical Co., Ltd.** · enrollment: 156 (estimated)

## Conditions studied

- Pupillary Dilation Effect During Cycloplegic Refraction

## Interventions

- **DRUG:** CTO0303-A
- **DRUG:** CTO0303-B
- **DRUG:** CTO0303-C

## Key facts

- **NCT ID:** NCT06609525
- **Lead sponsor:** Taejoon Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-05-09
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-03-01
- **Target enrollment:** 156 (ESTIMATED)
- **Last updated:** 2024-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06609525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06609525, "Comparing Efficacy and Safety of CTO0303 in Pediatric Subjects". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06609525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*